There’s a brand new sativa in town - Durbanex Flower T26% S 11464! Durbanex is a sister strain of our beloved Venomex and has 26.14% of THC and 0.72% terpenes. This pure sativa originates from South Africa and has buds that are round and chunky, and leave a thick coat of trichomes all over the plant.

This new indica is absolutely out of this world! Introducing the Astredex Flower T30% I 11432! This indica has dense buds, with deep purple hues and a coat of amber hairs. These ladies are covered in an astronomical amount of trichomes like a starry sky. Astredex has a sweet and herbal scent that reminiscent of fruits and vanilla. The taste further punctuates that fruit in the scent, with a smooth mouthfeel.

30.07% THC and 1.06% terpenes!

Happy VAPril and ApROLL!

Aproll and Vapril 2021 are putting the spotlight on our vape and pre-roll products!

Over the past year we have updated our vape cartridge packaging to environmentally friendly, paper tubes that are color-coded by strain to match our disposable vape products. Orange - sativa, blue - CBD, green - hybrid, purple - indica.

Pre-rolls have also been color-coded by strain and are now packaged in a protective metal tin, keeping everything fresh!

Shorties are our newest pre-roll product that offers 0.4g per unit, with 5 units per pack.

To celebrate Vapril and Aproll we have made four different styles of stickers that will be available in dispensaries at a first come, first serve basis. The first 10 patients to collect all four stickers will receive a custom CTPharma swag pack! To enter, post a photo to Instagram on your story or feed showing all four stickers and be sure to tag us. Happy sticker hunting!

The name “Tortaden” comes from the Spanish word “Torta” which translates to “Cake”. This pungent and sour hybrid strain is back! This batch of Tortaden has 32.45% THC and 1.20% terpenes. Tortaden is known to have very dense buds with amber hairs and glistening trichomes. The purplish leaves on this strain reflect some of its lineages as we describe below. This is only the second time we have grown this strain but we might put this one in the starting rotation!

Lineage:

This strain was created here at CTPharma by our expert cultivation team. After careful selection and deliberation, we determined that these two strains might play nice together and create powerful offspring. We crossed our high-powered Sativa strain, Tetraden, with our popular fan-favorite hybrid, Auralex to create this dank, sticky new strain for the CTMMP.

Tetraden: This strain is extremely pungent, so it’s best stored in tightly sealed containers. The pungent aroma of Sour Kush has a sweetly citrus scent akin to lemon and lime. The taste is a spicy citrus, some even claiming there are hints of garlic, with an expected aftertaste of diesel. The dense, pine cone-shaped nuggets feature dark green leaves with shades of deep purple, covered generously with cloudy, amber trichomes and strong orange hairs. Independent testing labs have reported flowers of this strain to have between 29 and 32% THC since we have been growing this.

Auralex: This strain leans on some very popular genetics to yield a balanced high and a dynamic taste. It gives an exceptionally sweet aromatic essence and a fruity flavor. The taste is a perfect combination of the sweetness of cookies and the fruitiness of a cherry pie. In terms of looks, it is quite frosty and has dark green leaves. Independent testing labs have reported flowers of this strain to have between 27 and a staggering 34% THC over the years.

Terpenes:

β-myrcene - 0.31, limonene - 0.30, linalool - 0.31, β-caryophyllene - 0.28 TOTAL TERPENES: 1.20%

Please visit the CT MMP page for more information.

For Adults, Debilitating Medical Conditions Include:

• Cancer (Effective 2012)

• Glaucoma (Effective 2012)

• Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)

• Parkinson's Disease (Effective 2012)

• Multiple Sclerosis (Effective 2012)

• Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)

• Epilepsy (Effective 2012)

• Cachexia (Effective 2012)

• Wasting Syndrome (Effective 2012)

• Crohn's Disease (Effective 2012)

• Post-Traumatic Stress Disorder (Effective 2012)

• Sickle Cell Disease (Effective 2016)*

• Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*

• Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*

• Amyotrophic Lateral Sclerosis (Effective 2016)*

• Ulcerative Colitis (Effective 2016)*

• Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*

• Cerebral Palsy (Effective 2016)

• Cystic Fibrosis (Effective 2016)

• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)

• Terminal Illness Requiring End-Of-Life Care (Effective 2016)

• Uncontrolled Intractable Seizure Disorder (Effective 2016)

• Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*

• Severe Rheumatoid Arthritis (Effective 2018)*

• Post Herpetic Neuralgia (Effective 2018)*

• Hydrocephalus with Intractable Headache (Effective 2018)*

• Intractable Headache Syndromes (Effective 2018)*

• Neuropathic Facial Pain (Effective 2018)*

• Muscular Dystrophy (Effective 2018)*

• Osteogenesis Imperfecta (Effective 2018)*

• Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*

• Interstitial Cystitis (Effective 2019)*

• MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*

• Vulvodynia and Vulvar Burning (Effective 2019)*

• Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*

• Tourette Syndrome (Effective 2019)*

• Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*

• Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*
  

For Patients Under 18, Debilitating Medical Conditions Include:

• Cerebral Palsy (Effective 2016)

• Cystic Fibrosis (Effective 2016)

• Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)

• Severe Epilepsy (Effective 2016)

• Terminal Illness Requiring End-Of-Life Care (Effective 2016)

• Uncontrolled Intractable Seizure Disorder (Effective 2016)

• Muscular Dystrophy (Effective 2018)*

• Osteogenesis Imperfecta (Effective 2018)*

• Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*

• Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*

* Conditions were approved by the Regulation Review Committee via the recommendation of the Board of Physicians and Commissioner of Consumer Protection.

Qualifications for a Registration Certificate:

• Qualifying patient must be a Connecticut resident.

• Qualifying patient cannot be an inmate confined in a correctional institution or facility under the supervision of the Connecticut Department of Corrections.

The year 2020 will be one to remember as a tough year for so many different reasons. For us, it was an even harder year as we lost our beloved co-founder and CEO, Tom Schultz. Our new t-shirt design honors our late CEO’s legacy. Beyond all the good he did in the CT MMJ program, Tom Schultz spent his younger days in Kenya (Africa) where he was a teacher in a high school in Nairobi. He spent three years there and summited Mount Kenya for the first time in 1972. He made it a regular thing to travel back frequently to climb it time and again over the years. Our t-shirts also include a tribute to these accomplishments - on the mountain, you will see a small flag bearing Tom’s initials - TS. We hope you will wear yours with pride as we, the team at CTPharma, do everyday.

---

One of our hottest topicals is back in action, the Mend T100C100 I Cooling Body Balm 10784!

Mend Balm is a cooling cannabinoid infused body balm made for topical use. The cool sensation will be refreshing anywhere you need it! Hands, heels, joints, back, etc., this smooth and creamy 1:1 balm will make your skin sing with joy.

---

---

CTPharma offers a variety of methods for patients to medicate. Here is an explanation of our products, how they work, and how to use them.

*Disclaimer: Product packaging subject to change. Not all products represented.*

---

Concentrates

Live Concentrates

Oils

Tablets

Drops, Tinctures & Sprays

Topicals

1. CTPharma Logo

2. Strain Name, Product Name

3. Product Potency

   • T36% refers to the product having 36% THC

4. Color Bar Indicator

   • Indica - Purple

   • Sativa - Orange

   • Hybrid - Green

5. Type & Approximate Potency

6. Date Tested

   • The approximate date that the product was tested by a state-approved laboratory.

7. Lot Number

   • The lot number is a combination of 4 numerical digits that are given to a group of products that were manufactured in the same batch.

8. NDC

   • 5 digit National Drug Code assigned to the product

9. Quantity

   • Refers to the amount of product per unit.

10. Expiration Date

    • The approximate date that the state-approved laboratory deems the product expired.

11.  Microbiology

    • Confirmation that the product has passed a microbiological test by the state-approved laboratory.

12. CTPharma Contact Info

13.  Cannabinoids

    • Percentage of each cannabinoid found in the product.

14. Terpenes

    • Percentage of each terpene found in the product as well as the total terpene percentage.